Annovis Bio Unveils New Clinical Data on Buntanetap at CTAD 2025
Annovis Bio Inc. will present new clinical data on buntanetap at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) conference in December 2025. The presentations will cover amyloid co-pathology and cognitive decline in Parkinson’s disease dementia patients, and a Phase 3 study on buntanetap's efficacy in Alzheimer’s treatment. The results will be shared at the CTAD conference.
Annovis Bio Inc. has announced two upcoming presentations at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) conference, scheduled for December 1-4, 2025, in San Diego, California. The first presentation will address amyloid co-pathology and cognitive decline in buntanetap-treated Parkinson’s disease dementia patients. The second presentation will discuss a double 6⁄18-month Phase 3 study designed to evaluate the symptomatic and potential disease-modifying efficacy of buntanetap in treating Alzheimer’s disease. The results from these studies will be presented at the CTAD conference. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9590780-en) on November 24, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
